NIFTY Pharma Prediction for Tomorrow 12 June 2026: Key Levels and Sector Outlook

June 11, 2026
Posted by: Ankit Jaiswal
Category: Market

NIFTY Pharma 24,306.95 (+0.60%) on 11 Jun. High 24,457.30, low 24,094.40. Cautiously Bullish. Support 24,100, resistance 24,460. SpaceX IPO 12 Jun.

The NIFTY Pharma prediction for tomorrow 12 June 2026 is Cautiously Bullish after the index closed at 24,306.95 (+0.60%) on 11 June 2026 with an intraday high of 24,457.30 and low of 24,094.40. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured. The NIFTY Pharma prediction for tomorrow is shaped by two macro variables: the confirmed US CPI (headline 4.2% YoY, core 0.2% MoM — soft below estimate) and the SpaceX Nasdaq listing on 12 June creating potential overnight US market volatility. Pre-Fed positioning ahead of June 16-17, 2026 is the dominant global theme. Ankit Jaiswal, Senior Research Analyst at Univest, and Kunal Singla, Associate Director at Univest, provide the key levels for the NIFTY Pharma prediction for tomorrow 12 June 2026.

Click Here – Get Free Investment Predictions

Table of Contents

Market Context: 11 June 2026 Session

Nifty 50: 23,161.60 (-0.23%). High 23,327.45, low 23,072.05 (Put OI held).
Bank Nifty: 55,176.75 (+0.14%). New recovery high 55,600.15. ICICI Bank +1.83% (high Rs 1,333.00). Pvt Bank +0.55%.
US CPI (May 2026): Headline 4.2% YoY (in-line). Core CPI 0.2% MoM — BELOW 0.3% estimate. Energy-driven not broad-based.
India VIX: 15.61 (prev 15.63). Stable and slightly lower.
Key global event tomorrow: SpaceX Nasdaq listing on 12 June; Fed meeting June 16-17, 2026.
No expiry tomorrow: 12 June is a regular Friday session. BSE Sensex weekly expired today (Thursday 11 June).

NIFTY Pharma Technical Levels for Tomorrow 12 June 2026

Parameter	Value
11 June Close	24,306.95
Previous Close (10 June)	24,160.75
Change	+0.60%
Intraday High	24,457.30
Intraday Low	24,094.40
Support 1	24,100
Support 2	23,800
Resistance 1	24,460
Resistance 2	24,700
Trend	Cautiously Bullish

3 Stocks Building Serious Momentum Right Now

Discover stocks investors are actively accumulating
High-conviction opportunities backed by research
Designed for the next phase of market growth

Top Stock Picks on Univest

See the Stocks →

NIFTY Pharma Prediction for Tomorrow: Sector Analysis

Ankit Jaiswal observes that the NIFTY Pharma prediction for tomorrow is anchored at 24,100 support. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured. A break above 24,460 confirms the NIFTY Pharma prediction for tomorrow recovery case.

Kunal Singla notes that the NIFTY Pharma prediction for tomorrow is also influenced by overnight global factors: SpaceX Nasdaq listing on 12 June and Dollar Index direction. USFDA drug approvals; defensive demand continuation as market remains cautious pre-Fed. He recommends checking GIFT Nifty at 9:00 AM IST before any NIFTY Pharma related positions tomorrow.

Catalyst for NIFTY Pharma Prediction for Tomorrow

USFDA drug approvals; defensive demand continuation as market remains cautious pre-Fed. These sector-specific catalysts combined with the US CPI (core 0.2% MoM soft) and SpaceX IPO will determine the NIFTY Pharma prediction for tomorrow 12 June 2026.

Check the Univest Screener for live NSE/BSE data

Conclusion

The NIFTY Pharma prediction for tomorrow 12 June 2026 is Cautiously Bullish with 24,100 as key support and 24,460 as resistance. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured. Data sourced from open public platforms including NSE and BSE — verify from official sources before decisions.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Disclaimer: The securities quoted are for illustration purposes only and are not recommendatory. This is for educational purposes only and shall not be considered as investment advice by Univest (Uniresearch Global Pvt Ltd, SEBI Registered Research Analyst INH000013776). Investments are subject to market risks. Data is sourced from open public platforms including NSE, BSE and MCX and may be subject to revision. Always verify from official exchange sources before any investment decision. Past performance is not indicative of future results.

Frequently Asked Questions

What is the NIFTY Pharma prediction for tomorrow 12 June 2026?

Ans. The NIFTY Pharma prediction for tomorrow is Cautiously Bullish. It closed at 24,306.95 (+0.60%) on 11 June with a high of 24,457.30 and low of 24,094.40. Support is 24,100 and resistance is 24,460. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured.

What are NIFTY Pharma support and resistance for tomorrow?

Ans. Support 1: 24,100. Support 2: 23,800. Resistance 1: 24,460. Resistance 2: 24,700. A break above 24,460 confirms the bullish case for the NIFTY Pharma prediction for tomorrow.

What drives the NIFTY Pharma prediction for tomorrow?

Ans. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured. The SpaceX Nasdaq listing on 12 June and pre-Fed positioning ahead of June 16-17, 2026 are the key global variables.

How does core CPI affect NIFTY Pharma prediction for tomorrow?

Ans. Core CPI at 0.2% MoM (below 0.3% estimate) reduces Fed hike fears, supporting rate-sensitive sectors. Hot headline CPI 4.2% YoY pressures cost-sensitive sectors. The net effect on NIFTY Pharma prediction for tomorrow depends on the sector’s specific sensitivity.

Is NIFTY Pharma bullish or bearish for 12 June 2026?

Ans. The NIFTY Pharma prediction for tomorrow is Cautiously Bullish. USFDA drug approvals; defensive demand continuation as market remains cautious pre-Fed are the key catalysts. VIX at 15.61 and Nifty at 23,161.60 set the broad backdrop.

What is the key catalyst for NIFTY Pharma prediction for tomorrow?

Ans. USFDA drug approvals; defensive demand continuation as market remains cautious pre-Fed. Additionally, SpaceX Nasdaq listing on 12 June creates overnight volatility that will influence global risk sentiment and FII flows into all NSE sectors.

What happened to NIFTY Pharma today 11 June 2026?

Ans. NIFTY Pharma closed at 24,306.95 (+0.60%) on 11 June with high 24,457.30 and low 24,094.40. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured.

What is the key risk for NIFTY Pharma prediction for tomorrow?

Ans. Primary risk: SpaceX IPO creating US market volatility and FII flow disruption. Secondary: hot headline CPI 4.2% YoY pressuring inflation-sensitive sectors. Use stop-losses at 24,100 for long positions in NIFTY Pharma tomorrow.

Download the Univest iOS App or Univest Android App to track NIFTY Pharma live price and get daily predictions.

NIFTY Pharma Prediction for Tomorrow

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.